Trial to Collect Safety Data and Sera for Immunogenicity Testing

Inclusion Criteria: * Participant is aged ≥ 6 months (24 weeks) to \< 36 months (3rd birthday). * Participant is considered to be in good health on the basis of reported medical history and limited physical examination. * Participant is available for the duration of the study. * Parent/legal acceptable representative is willing and able to provide informed consent. * Parent/legal acceptable representative is willing and able to meet protocol requirements. * Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg (5.5 lbs). Exclusion Criteria: * Reported allergy to egg proteins, chicken proteins, or any other constituent of the vaccine. * An acute illness with or without fever (For infants/toddlers: temperature ≥ 100.4 °F rectal; For children: temperature ≥ 99.5 °F oral/axillary) in the 72 hours preceding enrollment in the trial (Enrollment may be deferred). * Clinically significant findings in vital signs or review of systems (investigator judgment; defer or exclude). * Participation in any other interventional clinical trial within 30 days prior to enrollment up to termination of the subject's participation in the study. * Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth. * Personal or immediate family history of congenital immune deficiency. * Developmental delay, neurologic disorder, or seizure disorder. * Chronic medical, congenital, or developmental disorder. * Known human immunodeficiency virus (HIV)-positive mother. * Prior personal history of Guillain-Barré syndrome. * Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.